Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma

Malignant mesothelioma (MM) is a highly aggressive and resistant tumor. The prognostic role of key effectors of glycolytic metabolism in MM prompted our studies on the cytotoxicity of new inhibitors of glucose transporter type 1 (GLUT-1) and lactate dehydrogenase-A (LDH-A) in relation to ATP/NAD+ me...

Full description

Bibliographic Details
Main Authors: Avan, A. (Author), Franczak, M.A (Author), Giovannetti, E. (Author), Granchi, C. (Author), Harasim, G. (Author), Jedrzejewska, A. (Author), Krol, O. (Author), Minutolo, F. (Author), Peters, G.J (Author), Smolenski, R.T (Author), Zaffaroni, N. (Author)
Format: Article
Language:English
Published: MDPI 2023
Subjects:
Online Access:View Fulltext in Publisher
View in Scopus
LEADER 02871nam a2200337Ia 4500
001 10.3390-ijms24097771
008 230529s2023 CNT 000 0 und d
020 |a 16616596 (ISSN) 
245 1 0 |a Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma 
260 0 |b MDPI  |c 2023 
856 |z View Fulltext in Publisher  |u https://doi.org/10.3390/ijms24097771 
856 |z View in Scopus  |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159330063&doi=10.3390%2fijms24097771&partnerID=40&md5=80f78fe91d0ebb00628ad507528503b6 
520 3 |a Malignant mesothelioma (MM) is a highly aggressive and resistant tumor. The prognostic role of key effectors of glycolytic metabolism in MM prompted our studies on the cytotoxicity of new inhibitors of glucose transporter type 1 (GLUT-1) and lactate dehydrogenase-A (LDH-A) in relation to ATP/NAD+ metabolism, glycolysis and mitochondrial respiration. The antiproliferative activity of GLUT-1 (PGL13, PGL14) and LDH-A (NHI-1, NHI-2) inhibitors, alone and in combination, were tested with the sulforhodamine-B assay in peritoneal (MESO-II, STO) and pleural (NCI-H2052 and NCI-H28) MM and non-cancerous (HMEC-1) cells. Effects on energy metabolism were measured by both analysis of nucleotides using RP-HPLC and evaluation of glycolysis and respiration parameters using a Seahorse Analyzer system. All compounds reduced the growth of MM cells in the µmolar range. Interestingly, in H2052 cells, PGL14 decreased ATP concentration from 37 to 23 and NAD+ from 6.5 to 2.3 nmol/mg protein. NHI-2 reduced the ATP/ADP ratio by 76%. The metabolic effects of the inhibitors were stronger in pleural MM and in combination, while in HMEC-1 ATP reduction was 10% lower compared to that of the H2052 cells, and we observed a minor influence on mitochondrial respiration. To conclude, both inhibitors showed cytotoxicity in MM cells, associated with a decrease in ATP and NAD+, and were synergistic in the cells with the highest metabolic modulation. This underlines cellular energy metabolism as a potential target for combined treatments in selected cases of MM. © 2023 by the authors. 
650 0 4 |a anticancer treatment 
650 0 4 |a cancer metabolism 
650 0 4 |a chemoresistance 
650 0 4 |a glucose transporter type 1 
650 0 4 |a lactate dehydrogenase 
650 0 4 |a malignant mesothelioma 
700 1 0 |a Avan, A.  |e author 
700 1 0 |a Franczak, M.A.  |e author 
700 1 0 |a Giovannetti, E.  |e author 
700 1 0 |a Granchi, C.  |e author 
700 1 0 |a Harasim, G.  |e author 
700 1 0 |a Jedrzejewska, A.  |e author 
700 1 0 |a Krol, O.  |e author 
700 1 0 |a Minutolo, F.  |e author 
700 1 0 |a Peters, G.J.  |e author 
700 1 0 |a Smolenski, R.T.  |e author 
700 1 0 |a Zaffaroni, N.  |e author 
773 |t International Journal of Molecular Sciences